Biocept is a leading commercial provider of liquid biopsy testing services designed to enable oncologists to rapidly detect and monitor cancer biomarkers from a simple blood sample. Through our Target Selector™ liquid biopsy, Biocept’s test menu focuses on cancer biomarkers that are clinically actionable based on clinical treatment guidelines listed by the National Comprehensive Cancer Network (NCCN).
Using every tool available to deliver the most accurate and complete results, we leverage the right technology for the right test. Learn more about our technology options.
Benefits
CTC Tests
CTCs obtained through our platform can be used to molecularly characterize tumor cells and evaluate changes in protein expression with the same techniques done in tissue.
The same specimen can be microscopically analyzed for DNA and protein targets.
All CTC tests are enumerated and can be used in monitoring applications.
Benefits
ctDNA Tests
Performing PCR upfront and then sequencing delivers added confidence to final result.
Switch-Blocker technology enriches oncogene mutations and suppresses wild type DNA resulting in ultra-high sensitivity and specificity.
All ctDNA tests are quantitative and can be used to monitor mutation load.
NGS technology allows multiplexing capabilities and future panel development.
Complete Platform
CTC Platform
- Translocations
- DNA Amplifications
- Protein Expression
ctDNA PLATFORM
- Single Nucleotide Variants (SNVs)
- Insertions
- Deletions
Partner with Biocept
Contact us to learn how Biocept can support your research and testing.
Contact Mike Terry, Senior Vice President, Corporate Development, for more information at 858.320.8200 Ext. 297 or via email at mterry@biocept.com.